NIITSU YOSHIRO has a total of 18 patent applications. Its first patent ever was published in 2002. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Argentina. Its main competitors in its focus markets pharmaceuticals, biotechnology and machines are NASTECH PHARM CO, BESTEWIL HOLDING BV and RODOS BIOTARGET GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 14 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Argentina | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Machines | |
#4 | Organic fine chemistry | |
#5 | Foods and drinks | |
#6 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Unspecified technologies | |
#5 | Unspecified technologies | |
#6 | Enzymes | |
#7 | Sugars | |
#8 | Acyclic or carbocyclic compounds | |
#9 | Analysing materials | |
#10 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Niitsu Yoshiro | 18 |
#2 | Tanaka Yasunobu | 6 |
#3 | Knopov Victor | 4 |
#4 | Perelman Loren A | 4 |
#5 | Ahmadian Mohammad | 4 |
#6 | Witte Richard P | 4 |
#7 | Akopian Violetta | 4 |
#8 | Payne Joseph E | 4 |
#9 | Takimoto Rishu | 4 |
#10 | Kato Junji | 3 |
Publication | Filing date | Title |
---|---|---|
WO2020009189A1 | Drug for inhibiting paradoxical growth of cancer cells caused by braf inhibitor | |
WO2019117188A1 | Cell proliferation inhibitor and cancer treatment or prevention pharmaceutical composition including cell proliferation inhibitor | |
US2012269886A1 | Therapeutic agent for pulmonary fibrosis | |
US2013022665A1 | Cationic lipids for therapeutic agent delivery formulations | |
US2013017249A1 | Compounds for targeting drug delivery and enhancing siRNA activity | |
WO03097097A1 | Method of treating and/or preventing acute leukemia using medicinal composition for therapeutic use containing vla4 antagonist, and method of diagnosing prognosis of acute leukemia using vla4 as indication |